Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DQRF for Vulvo-vaginal Atrophy (ViViA)
NCT03857893Terminated
- Start
- Mar 2019
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
Randomised, open-label trial in Vulvovaginal atrophy (VVA) (2 arms). Primary endpoints: Self-assessment of most bothersome symptom dyspareunia at 16 weeks, Vaginal cell maturation at 16 weeks and 1 more. Started Mar 2019; status: terminated.
02
Conditions
Vulvovaginal atrophy (VVA)
Beyond the preview
Go deeper on NCT03857893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03857893.